The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Image Credit: Caroline Ruda/Shutterstock.com A recent JAMA Network Open study investigated the factors associated with discontinuation and subsequent reinitiation of GLP-1 RAs among overweight or ...

Adverse effects, warnings and precautions, and contraindications of compounded GLP-1 RAs were not reported by 39 websites (49.4 percent), while 32 sites advertised an efficacy claim not in the ...